Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TAGRAXOFUSP
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Study of Tagraxofusp in Newly Diagnosed Secondary AML After Previous Exposure to Hypomethylating Agents
- Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)
- Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
- Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Tagraxofusp (SL-401) in Patients With CMML or MF
Clinical trials list
click for details